Biarylacetamides: a novel class of late-stage autophagy inhibitors

Biarylacetamides: a novel class of late-stage autophagy inhibitors

Targeting autophagy is believed to hold great promise for the treatment of various diseases, including cancer. However, since the therapeutic efficacy of currently available autophagy-modulating drugs is limited by off-target effects and the requirement of high dosage, there is an urgent need to dev...

Full description

Saved in:
Bibliographic Details
Main Authors: Mélissa Lallier, Rani Robeyns, Freke Mertens, Angela Sisto, Guido R.Y. De Meyer, Koen Augustyns, Maya Berg, Winnok H. De Vos, Vincent Timmerman, George M.C. Janssen, Peter van Veelen, Alexander L.N. van Nuijs, Nikolai Engedal, Wim Martinet, Pieter Van der Veken
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Autophagy Reports
Subjects:
Autophagy inhibitor
biarylacetamide derivatives
proteomics
metabolomics
lipidomics
cholesterol biosynthesis
Online Access:https://www.tandfonline.com/doi/10.1080/27694127.2025.2541597
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/27694127.2025.2541597

Similar Items